News

AI and semiconductor stocks are overvalued and shifting to healthcare stocks like Eli Lilly and Company could be wise. Click ...
Donanemab, approved by the FDA in 2024 to treat Alzheimer's disease, is a monoclonal antibody directed at N-terminally ...
At AAIC, Lilly highlighted benefits of being able to stop Kisunla, while Eisai made a case for subcutaneous Leqembi, which is ...
Blarcamesine appeared to slow the decline of cognition and functional capacity for people with Alzheimer’s disease in a ...
When you only buy stocks that you have strong convictions about as long-term investments (based on sound research, your ...
Blarcasemine met its primary endpoints, improving cognition and function over a four year period in early-stage Alzheimer’s patients.
Eli Lilly’s Alzheimer’s disease (AD) drug donanemab has been recommended by the European Medicines Agency’s human medicines ...